RotaTeq recommended
Executive Summary
Merck's rotavirus vaccine RotaTeq was recommended for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices Feb. 21. The committee voted 12-0 with two abstentions for routine immunization of infants with three doses of the oral vaccine to be administered at two, four and six months of age. CDC analysis found that RotaTeq was not cost effective at the published price of $62 per dose, but could be cost effective at $42 per dose. RotaTeq was approved in early February (1"The Pink Sheet" Feb. 12, 2006, p. 25)...
You may also be interested in...
Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads
Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.